Please use this identifier to cite or link to this item:
|Title:||Production of Alpha Emitting Radionuclides for Nuclear Medicine|
|Authors:||MORGENSTERN Alfred; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank|
|Publisher:||European Commission - Joint Research Centre - Institute for Transuranium Elements|
|Type:||Articles in periodicals and books|
|Abstract:||Targeted alpha therapy (TAT) is a novel approach for the treatment of cancer and infectious diseases based on the coupling of alpha particle emitting radioisotopes to target selective carrier molecules. Taking advantage of the short range (< 100 ¿m) and high linear energy transfer (LET ¿ 100 keV/¿m) of alpha particles in human tissue, targeted alpha therapy offers the potential of delivering a highly cytotoxic dose to targeted cells while minimizing damage to surrounding healthy tissue. The efficacy and safety of TAT has been shown in a number of pre-clinical studies and has to date been translated to clinical trials of leukemia, malignant melanoma, lymphoma, glioma, ovarian cancer and skeletal metastases [1-10]. For the further development and widespread application of TAT, the availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite. Here we describe the principle of TAT and give an overview on methods for the production of suitable radionuclides, including 225Ac / 213Bi, 230U / 226Th, 227Th / 223Ra, 212Pb / 212Bi, 211At and 149Tb.|
|JRC Directorate:||Nuclear Safety and Security|
Files in This Item:
There are no files associated with this item.
Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.